0001567619-22-009865.txt : 20220509 0001567619-22-009865.hdr.sgml : 20220509 20220509212946 ACCESSION NUMBER: 0001567619-22-009865 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220429 FILED AS OF DATE: 20220509 DATE AS OF CHANGE: 20220509 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: BIENAIME JEAN JACQUES CENTRAL INDEX KEY: 0001221590 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-26727 FILM NUMBER: 22907074 MAIL ADDRESS: STREET 1: 925 PAGE MILL ROAD CITY: PALO ALTO STATE: CA ZIP: 94304 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: BIOMARIN PHARMACEUTICAL INC CENTRAL INDEX KEY: 0001048477 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 680397820 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 105 DIGITAL DRIVE CITY: NOVATO STATE: CA ZIP: 94949 BUSINESS PHONE: 4155066700 MAIL ADDRESS: STREET 1: 105 DIGITAL DRIVE CITY: NOVATO STATE: CA ZIP: 94949 4 1 doc1.xml FORM 4 X0306 4 2022-04-29 0 0001048477 BIOMARIN PHARMACEUTICAL INC BMRN 0001221590 BIENAIME JEAN JACQUES C/O BIOMARIN PHARMACEUTICAL INC. 770 LINDARO ST. SAN RAFAEL CA 94901 1 1 0 0 Chief Executive Officer Common Stock 2022-04-29 5 A 0 341 62.407 A 335324 D Common Stock 2022-05-05 4 M 0 10000 37.46 A 345324 D Common Stock 2022-05-05 4 S 0 10000 84.14 D 335324 D Common Stock 2022-05-06 4 M 0 20000 37.46 A 355324 D Common Stock 2022-05-06 4 S 0 20000 81.00 D 335324 D Common Stock 247533 I Shares held by Jean-Jacques Bienaime Family Trust Stock Option (Right to buy Common Stock) 37.46 2022-05-05 4 M 0 10000 0 D 2012-11-08 2022-05-07 Common Stock 10000 20000 D Stock Option (Right to buy Common Stock) 37.46 2022-05-06 4 M 0 20000 0 D 2012-11-08 2022-05-07 Common Stock 20000 0 D Represents shares acquired by the reporting person on April 29, 2022, pursuant to the issuer's Employee Stock Purchase Plan. Trade made pursuant to a 10b5-1 plan executed on December 9, 2021, as amended on March 11, 2022. Trade made pursuant to a 10b5-1 plan executed on December 9, 2021, as amended on March 11, 2022. Mr. Bienaime's former spouse will receive approximately 73% of the net proceeds from the shares sold in this transaction pursuant to a marital separation agreement between her and Mr. Bienaime. Reflects the number of options outstanding after the transactions from this specific stock option grant. /s/ Laura Randall Woodhead, Attorney-in-Fact 2022-05-09